Skip to main content
PROK logo

PROK · Prokidney Corp.

Track PROK — free
$1.06 +0.02 (+1.92%)
Market Cap
$320.52M
Shares
302.38M
Volume · Nov 19 1.65M Avg daily vol (3M) 1.44M

Price & Indicators

Drag to pan · scroll to zoom
20d MA 50d MA 200d MA Earnings Filing Insider Congress Investor day
Close$1.06 Open$1.07 Day$1.02–1.13 52W close$1.04–2.57 Avg vol 30d1.4M Short int24.3M · 8.0% of shares · 22.5d Short vol83% Last earningsMay 10, 2024 DataJun 2021–Nov 2026 Filing10-Q · Nov 12

Up next

call held Nov 14, 2023

Latest documents

2026
Nov 12
Current report 8-K
PROACT 1 eGFR readout remains on track for Q2 2027

ProKidney reported $51.8 million net loss before noncontrolling interest for the quarter ended September 30, 2026, with $141.9 million in cash, cash equivalents and marketable securities. PROACT 1 remains on track for an eGFR slope topline readout in Q2 2027.

Financial results
4 source passages
ProKidney Corp. (Nasdaq: PROK) (“ProKidney” or the "Company"), a leading late clinical-stage cell therapy company focused on chronic kidney disease (CKD), today reported financial results for the third quarter ended September 30, 2026 and provided business highlights and upcoming milestones. Liquidity: Cash, cash equivalents and marketable securities as of September 30, 2026, totaled $141.9 million, compared to $181.6 million as of June 30, 2026. Net Loss Before Noncontrolling Interest: Net loss before noncontrolling interest was $51.8 million and $35.8 million for the three months ended September 30, 2026 and 2025, respectively. On track to deliver pivotal Phase 3 PROACT 1 surrogate endpoint (eGFR slope) topline results in Q2 2027; the efficacy analysis set is expected to include approximately 320 patients Open the document at this passage
Nov 12
Quarterly report 10-Q FY2026 Q3, ended Sep 30
Going-concern doubt as Phase 3 PROACT 1 advances

ProKidney Corp. faces substantial going-concern doubt and expects existing cash, cash equivalents and marketable securities to fund operations into mid-2027. PROACT 1 Phase 3 surrogate-endpoint data are expected in the second quarter of 2027.

Revenue $174K ▼ 19.8% Net loss $35.59M
Read from the MD&A section
4 source passages
Accordingly, substantial doubt exists about our ability to continue as a going concern within one year after the date the unaudited condensed consolidated financial statements included elsewhere in this Quarterly Report on Form 10-Q are issued. We expect that our existing cash, cash equivalents and marketable securities held at September 30, 2026, will enable us to fund our operating expenses and capital expenditure requirements into mid-2027. Our lead product candidate, rilparencel, is being evaluated in the ongoing Phase 3 REGEN-006 (PROACT 1) clinical study in participants with advanced CKD and type 2 diabetes. We anticipate topline data readout of the surrogate endpoint (eGFR slope) in the second quarter of 2027 Open the document at this passage
Nov 9
Investor event
Q1 2027 enrollment and Q2 of next year approval readout

ProKidney expects enrollment to finish in Q1 2027 and an accelerated approval readout in Q2 of next year. Cash of $142 million at the end of September is expected to support operations through mid-2027 after the readout.

5 source passages
Next to me, we have Bruce Culleton, the CEO, and then we have Anthony Conway, head of R&D, and then we have Greg Madison on the CCO at the end of the group here. We should finish enrollment in Q1 2027 That's the accelerated approval readout, which is, again, expected in Q2 of next year. In our corporate deck this morning, we released our position that we had $142 million in cash at the end of September. That's sufficient cash to take us out to mid-2027 after a readout. Open the document at this passage
Nov 9
Current report 8-K
Phase 3 PROACT 1 data expected in Q2 2027

ProKidney Corp. expects Phase 3 PROACT 1 topline data in Q2 2027, with cash, cash equivalents and marketable securities of $141.9 million expected to fund operations into mid-2027.

Financial results, Regulation FD disclosure, Other events
4 source passages
ProKidney Corp. (the “Company”) has updated its investor presentation (the “Presentation”), which its senior management intends to use from time to time when interacting with investors and analysts, among others. The Company's cash and cash equivalents and marketable securities as of September 30, 2026 was $141.9 million. Q2 2027 Topline readout for the Phase 3 PROACT 1 surrogate endpoint (eGFR slope) for accelerated approval. including the Company’s expectation that current cash will support operating plans into mid-2027 Open the document at this passage
Oct 29
Current report 8-K
Agreement with Jefferies allows up to $200,000,000 in at-the-market stock sales

ProKidney entered an Open Market Sale Agreement with Jefferies LLC allowing it to sell Class A common stock up to $200,000,000 in aggregate offering price. Sales depend on effectiveness of a Form S-3 shelf registration filed October 29, 2026.

Entered into a material agreement
3 source passages
On October 29, 2026, ProKidney Corp. (the “Company”) entered into an Open Market Sale Agreement^SM^ (the “Sales Agreement”) with Jefferies LLC (the “Sales Agent”), pursuant to which the Company may offer and sell, from time to time, shares (the “Shares”) of its Class A common stock, par value $0.0001 per share, through the Sales Agent, acting as agent. the Company may offer and sell Shares pursuant to the Sales Agreement Prospectus of up to a maximum aggregate offering price of $200,000,000 from time to time under the Sales Agreement with the Sales Agent. The issuance and sale, if any, of the Shares under the Sales Agreement is subject to the effectiveness of the Company’s shelf registration statement on Form S-3, which was filed with the United States Securities and Exchange Commission (the “SEC”) on October 29, 2026 Open the document at this passage
All documents

Metrics snapshot

Useful current figures from the complete screener profile.

Revenue (TTM)
$775,000
Trailing 12 months
Net income (TTM)
−$103.28M
Trailing 12 months
Revenue growth YoY
-19.8%
Year over year
Operating margin
-24,830.3%
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
-53.4%
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
$81.36M
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
-54.4%
Trailing year
Short interest
8.0%
Latest settlement · 22.5 days to cover
View all 125 metrics

Equibles Rating

blended score · not investment advice
Overall
Sell
SellHoldBuy
Technical Sell Momentum Very Weak Sentiment Bullish Fundamentals Fair Quant / Vol Very High
Market backdrop VIX 24.6 · elevated Equity put/call 0.72
Technical
price trend
Sell
50 / 200-day cross No cross
Price vs 200-day avg −39%
below
Price vs 50-day avg −27%
below
RSI (14) 37
neutral
MACD trend Positive
52-week position 1%
near low
Volume (OBV) Confirms
volume backs price
Momentum
relative strength
Very Weak
1-month return −26%
trailing
6-month return −43%
trailing
YTD return −53%
this year
Relative strength −37%
vs S&P · 6-mo
Sentiment
smart money
Bullish
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+29% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.05% of shares out · ▼ -0.9% MoM · 22.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
93 holders — near 5-yr high, broad support
Squeeze score 64
elevated · 0–100
Fundamentals
Fair
Revenue growth +1075%
Y/Y
Free cash flow $-135.3M
Quant / Vol
risk profile
Very High
Volatility 73%
annualized · 1-yr
Max drawdown −60%
past year
ATR 11.3%
of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Technicals

trend & momentum for long-term holders Sell
3 · 3 · 1
50 / 200-day cross
No cross Neutral
Price vs 200-day avg
−39% Bearish
Price vs 50-day avg
−27% Bearish
RSI (14)
37 Neutral
MACD trend
Positive Bullish
52-week position
1% Bearish
Volume (OBV)
Confirms Neutral
Market signals — smart money & positioning
Bullish · 3 of 6
Trend (MA cross) No cross
50d $1 › 200d $2 — 200d above 50d
Institutional flow Accumulating
+29% holders QoQ · +26 funds added
Insider flow Flat
No net insider activity over 90 days
Short interest Falling
8.05% of shares out · ▼ -0.9% MoM · 22.5 days cover
Volume signal Normal
Volume near normal
Institution breadth Multi-yr high
93 holders — near 5-yr high, broad support
Price context
position in its 52-week range
Range low $1 Now $1 · 1% Range high $3
vs 200-day avg -39% vs 50-day avg -27%

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings
Metric Latest Period YoY
Class A and Class B common stock outstanding 302,371,200 as of September 30, 2026 —
Total equity-based compensation expense $5.88M the three months ended September 30, 2026 filing —
Weighted average shares of Class A common stock outstanding, basic and diluted 207,760,422 the three months ended September 30, 2026 filing —
Cash and cash equivalents and marketable securities $141.9M as of September 30, 2026 —
Shares Outstanding 302,381,712 as of November 6, 2026 —

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group
Open screener →
Company Mkt cap YTD Rev growth Y/Y P/E Short % shares
PROK
Prokidney Corp.
this stock
$320.52M -52.7% +1075.0% — 8.0%
VRTX
Vertex Pharmaceuticals Inc
$132.01B +14.8% +46.2% 33.5 1.9%
REGN
Regeneron Pharmaceuticals, Inc.
$95.52B +19.6% +20.8% 20.4 2.1%
MRNA
Moderna, Inc.
$80.65B +575.9% +4.3% — 8.2%
CSLLY
Csl Ltd
$63.15B — — — 0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section
Ownership
Institutional Holders Accumulating
Holders
93
% held
18.1%
Net QoQ
+6.7M sh
Top holder
SUVRETTA CAPITAL MANAGEME…
Held Float
View
Held by Funds
Fund positions
84
View
Short & Settlement
Short Interest Falling
Shares short
24.3M
Days to cover
22.5d
Change
-230.2K sh
View
Short Volume
Short vol %
83%
As of
Nov 18, 2026
Short Total
View
Fails to Deliver
FTD shares
292.5K
Value
$429.9K
As of
Oct 30, 2026
View
Off-Exchange
Off-exchange %
45.6%
Week of
Oct 12, 2026
Off-exch Lit
View
Financials
Financials
Net income (FY)
$-69.0M
EPS diluted
$-0.23
View
Filings
SEC Filings
Latest
10-Q
Filed
Nov 12, 2026
This year
19

ProKidney Corp. faces substantial going-concern doubt and expects existing cash, cash equivalents and marketable securities to fund operations into mid-2027. PROACT 1 Phase 3 surrogate-endpoint data are expected in the second quarter of 2027.

View
Proposed Sales
Value
$221.2K
Shares
81.9K
Filed
Nov 12, 2025
View
Earnings & Events
Webcasts Upcoming
Next webcast
Dec 2, 2026
Last webcast
Nov 16, 2026
View
Investor Relations
Latest news
ProKidney Reports Third Quarter 2…
Published
Nov 12, 2026
Upcoming events
1
View

Performance

5D 20D 120D MTD YTD
PROK -7.8% -25.9% -42.7% -18.2% -52.7%
SPY -5.5% -6.3% -5.6% -5.3% +5.0%
vs SPY -2.4% -19.6% -37.1% -12.9% -57.7%
Key facts CIK 1850270 CUSIP 74291D104 13F (30d) 89 filings 85 filers Visit website Investor relations